These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 35890368)

  • 1. Novel Treatments for Age-Related Macular Degeneration: A Review of Clinical Advances in Sustained Drug Delivery Systems.
    Jiménez-Gómez Y; Alba-Molina D; Blanco-Blanco M; Pérez-Fajardo L; Reyes-Ortega F; Ortega-Llamas L; Villalba-González M; Fernández-Choquet de Isla I; Pugliese F; Stoikow I; González-Andrades M
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Approaches in the Drug Development and Delivery Systems for Age-Related Macular Degeneration.
    Paliwal H; Prajapati BG; Srichana T; Singh S; Patel RJ
    Life (Basel); 2023 Feb; 13(2):. PubMed ID: 36836923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging innovations in nano-enabled therapy against age-related macular degeneration: A paradigm shift.
    Kumar Dubey S; Pradhan R; Hejmady S; Singhvi G; Choudhury H; Gorain B; Kesharwani P
    Int J Pharm; 2021 May; 600():120499. PubMed ID: 33753164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.
    Yeong JL; Loveman E; Colquitt JL; Royle P; Waugh N; Lois N
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013154. PubMed ID: 33331670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the management of dry age-related macular degeneration: A review.
    Bandello F; Sacconi R; Querques L; Corbelli E; Cicinelli MV; Querques G
    F1000Res; 2017; 6():245. PubMed ID: 28529701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optical coherence tomography for age-related macular degeneration and diabetic macular edema: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(13):1-22. PubMed ID: 23074517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dry Age-Related Macular Degeneration Pharmacology.
    Wright CB; Ambati J
    Handb Exp Pharmacol; 2017; 242():321-336. PubMed ID: 27900609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel approach to antiangiogenic factors in age-related macular degeneration therapy.
    Samelska K; Kupis M; Izdebska J; Kaminska A; Skopiński P
    Cent Eur J Immunol; 2022; 47(1):117-123. PubMed ID: 35600160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD).
    Patel P; Sheth V
    J Clin Med; 2021 May; 10(11):. PubMed ID: 34070899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review.
    Waugh N; Loveman E; Colquitt J; Royle P; Yeong JL; Hoad G; Lois N
    Health Technol Assess; 2018 May; 22(27):1-168. PubMed ID: 29846169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dry age-related macular degeneration: A currently unmet clinical need.
    Girmens JF; Sahel JA; Marazova K
    Intractable Rare Dis Res; 2012 Aug; 1(3):103-14. PubMed ID: 25343081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-related macular degeneration--emerging pathogenetic and therapeutic concepts.
    Gehrs KM; Anderson DH; Johnson LV; Hageman GS
    Ann Med; 2006; 38(7):450-71. PubMed ID: 17101537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Novel approach for management of age-related macular degeneration--antiangiogenic therapy and retinal regenerative therapy].
    Tamaki Y
    Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):232-68; discussion 269. PubMed ID: 17402564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline.
    Kaiser PK
    Ophthalmology; 2013 May; 120(5 Suppl):S11-5. PubMed ID: 23642781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genetics of age-related macular degeneration (AMD)--Novel targets for designing treatment options?
    Grassmann F; Fauser S; Weber BH
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):194-202. PubMed ID: 25986585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept for neovascular age-related macular degeneration.
    Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current therapeutic approaches in neovascular age-related macular degeneration.
    Nguyen DH; Luo J; Zhang K; Zhang M
    Discov Med; 2013 Jun; 15(85):343-8. PubMed ID: 23819948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects.
    Danis RP; Lavine JA; Domalpally A
    Clin Ophthalmol; 2015; 9():2159-74. PubMed ID: 26640366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration.
    Tolentino MJ; Dennrick A; John E; Tolentino MS
    Expert Opin Investig Drugs; 2015 Feb; 24(2):183-99. PubMed ID: 25243494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neovascular age-related macular degeneration: potential therapies.
    Chappelow AV; Kaiser PK
    Drugs; 2008; 68(8):1029-36. PubMed ID: 18484796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.